|
0730-1500
|
|
Semi-Live Surgery
Co-Chairs: Melanie Aube-Peterkin, Canada / Jean de la Rosette, Turkey / Rafael Sanchez-Salas, Canada
|
|
Learning Objectives:
At the end of this course, participants should be able to:
- Recognize important perioperative considerations and techniques for reconstructive urologic surgery, including selecting the best reconstructive approach to optimize treatment outcomes.
- Demonstrate practical knowledge of instrumentation and techniques for the endourologic treatment of upper and lower urinary tract conditions, including the management of special clinical cases.
- Examine the role of micro-ultrasound and focal therapy approaches in the management of radiorecurrent prostate cancer.
- Recognize the advantages and limitations of open surgery, laparoscopic, and robotic-assisted procedures in uro-oncology, with respect to novel devices, instrumentation, and techniques.
- Evaluate their own role in patient management, from multidisciplinary care to treatment outcomes, based on the clinical experience of key opinion leaders in the surgical management of urologic conditions.
|
|
0730-0945
|
|
Endourology
Moderators
Madhu Agrawal, India
Ben Chew, Canada
|
|
|
|
Procedures:
|
|
|
|
Prostate enucleation: HoLEP en-bloc procedure +/- low-power HoLEP vs. Soltive ThuFLEP and bladder stone dusting
|
|
|
|
HoLEP
Surgeon: Hugo de la Rosa, Mexico
|
|
|
|
ThuFLEP
Surgeon: Naeem Bhojani, Canada
|
|
|
|
Rezūm
Surgeon: Dean Elterman, Canada
|
|
|
|
Stones: Focus on Special Cases
|
|
|
|
PCNL in Staghorn Stones
Surgeon: Sven Lahme, Germany
|
|
|
|
PCNL in pediatric patients
Surgeon: Sanjay Khadgi, Nepal
|
|
|
|
Single-use ureteroscope for stone management
|
|
|
|
Different access sheaths for PCNL
Surgeon: Guohua Zeng, China
|
|
|
|
Thulium fiber laser for kidney stones
Surgeon: Dimitry Enikeev, Russia
|
|
0945-1115
|
|
Focal Therapy and Imaging in Radiorecurrent Disease
Moderator: Jurgen Futterer, The Netherlands
|
|
|
|
Procedures:
|
|
|
|
Micro-Ultrasound
|
|
|
|
Cryotherapy
Surgeon: José Gadú Campos, Mexico
|
|
|
|
HIFU, Focal One
Surgeon: Sébastien Crouzet, France
|
|
1115-1330
|
|
Uro-Oncology
Gustavo Villoldo, Argentina
Moderator: Pilar Laguna, Turkey
|
|
|
|
Procedures:
|
|
|
|
Simulation Training
Surgeon: Gonzalo Vitagliano, Argentina
|
|
|
|
Open vs. robotic vs. laparoscopic - three procedures presented simultaneously.
|
|
|
|
Open
Surgeon: Gennady Bratslavsky, United States
|
|
|
|
Robotic
Surgeon: Elias Bodden, Germany
|
|
|
|
Laparoscopic
Surgeon: Petr Macek, France
|
|
|
|
Robotic radical prostatectomy
Surgeon: Ruben Olivares, United States
|
|
1330-1500
|
|
Reconstructive Surgery
Moderators
Melanie Aube-Peterkin, Canada
Anthony Mundy, United Kingdom
|
|
|
|
Vaginal reconstruction with autologous sling
Surgeon: Lysanne Campeau, Canada
|
|
|
|
Penile urethroplasty: Kulkarni technique
Surgeon: Sanjay Kulkarni, India
|
|
|
|
Penile prosthesis implantation: AMS
Surgeon: Daniel Rosenstein, United States
|
|
|
|
Penile prosthesis implantation: Titan
Surgeon: Koenraad van Renterghem, Belgium
|
|
|
|
Urethral strictures: Optilume
Surgeon: Merycarla Pichardo, Dominican Republic
|
|
|
|
Holmium laser bladder neck incision
Surgeon: Ramon Virasoro, United States
|
|
|
0800-0930
|
|
Instructional Course: Evaluation and Management of Non-neurogenic Female Bladder Outlet Obstruction (BOO)
Chair: Lysanne Campeau, Canada
|
|
Learning Objectives:
At the end of this session, attendees will be able to:
- Understand the pathophysiology of female BOO
- Describe the various causes of female BOO
- Carry out appropriate investigations for female BOO
- Describe various medical treatment of female BOO
- Describe various surgical treatments of female BOO
|
|
0800-0803
|
|
Introduction and Welcome
Lysanne Campeau, Canada
|
|
0803-0808
|
|
Evaluation of female patients with BOO (History, physical examination and basic investigations)
Ali Alsulihem, Saudi Arabia
|
|
0808-0820
|
|
Discussion
|
|
0820-0827
|
|
Differential diagnosis of Female BOO
Lysanne Campeau, Canada
|
|
0827-0832
|
|
Advanced Evaluation (Video urodynamics, and cystoscopy) in female BOO
Jacques Corcos, Canada
|
|
0832-0844
|
|
Discussion
|
|
0844-0854
|
|
Conservative and medical management of Female BOO
Lysanne Campeau, Canada
|
|
0854-0904
|
|
Surgical management of Female BOO
Ali Alsulihem, Saudi Arabia
Jacques Corcos, Canada
|
|
0904-0928
|
|
Cases for interaction and discussion
|
|
0928-0930
|
|
Wrap up and Evaluation
Lysanne Campeau, Canada
|
|
|
0800-0930
|
|
Instructional Course: Male Infertility and Assisted Reproductive Technology
Chair: Taras Shatylko, Russia
|
|
Learning Objectives:
By the end of this session, attendees will be able to:
- Assess reproductive prognosis of an infertile male
- Identify andrological indications for assisted reproductive technologies
- Understand how female infertility affects decision-making in reproductive urology
- Interact with gynecologist to improve reproductive outcomes of an infertile couple
- Recognize indications and technical details of common surgical sperm retrieval methods
|
|
0800-1000
|
|
Canadian Urological Association (CUA) Symposium
Co-Chairs: Armen Aprikian, Canada / Ricardo Rendon, Canada
|
|
Learning Objectives:
At the of this symposium, participants should be able to:
- Recognize the role of germline mutations underlying predisposition for urologic oncology as well as implications for early detection of disease and ethical considerations in patient care.
- Identify germline and somatic mutations of BRCA and related genes with clinical relevance for treatment decision-making in prostate cancer.
- Summarize the utility of molecular subtyping for guiding prognosis and treatment decision-making in bladder cancer and kidney cancer.
- Recall the emerging role of precision medicine in urologic oncology and key considerations for its implementation in the clinical practice.
|
|
0800-1000
|
|
Interactive Session: Bladder Pain Syndrome and Interstitial Cystitis
Co-Chairs: Roger Dmochowski, United States / Rajesh Taneja, India
|
|
Learning Objectives:
At the end of this session, participants should be able to:
- To introduce the topic, which is usually much less discussed than required. Since this is a disease which is primarily a clinical diagnosis, and the one which is made by exclusion of other diseases, it is important to sensitize the clinicians about the real-world scenario. The prevalence estimates range from 2.7% to 6.53% in women of age 18 years or older in the United States to 306/100 000 women in Vienna (1,2)
- The nomenclature of this disease entity has been evolving. We need to have a balanced approach to discuss how it is perceived in various parts of world (3)
- These are heterogenous group of patients and consequently the etiopathogensis of the symptoms is variable. Through this symposium, an attempt would be made to discuss the varied pathogenic mechanism leading to the clinical picture. (4 )
- Since this is a heterogeneous entity, no single modality of treatment is likely to benefit these patients. An outline of treatment modalities, along with some newer methods including self-intravesical instillations will be discussed. ( 5,6)
|
|
|
|
1. Nomenclature of bladder pain syndrome – the concept of Hypersensitive Bladder
|
|
|
|
2. Pathophysiology of IC/BPS
|
|
|
|
3. Clinical Approach to a suspected IC/BPS
|
|
|
|
4. Cystoscopy in IC /BPS
Shingai Mutambirwa, South Africa
|
|
|
|
5. Management of IC/BPS
|
|
|
|
6. Self help in intravesical treatment. What is on the horizon
Sandor Lovasz, Hungary
|
|
|
|
Interactive panel discussion
|
|
|
0800-1000
|
|
SIU Tips and Tricks - Pt 1 SIU Academy
Chair: Faysal Yafi, United States
|
|
0800-1000
|
|
Workshop: Basics in Endourology (For the Beginners) - Session 1
Coordinators: Belthangady Monu Zeeshan Hameed, India / Dilip Mishra, India / Amelia Pietropaolo, United Kingdom
|
|
0800-1200
|
|
International Consultation on Urological Diseases (ICUD) and World Urologic Oncology Federation (WUOF) - Consultation: Kidney Cancer
|
|
0800-1200
|
|
Joint International Society of Reconstructive Urology (ISORU) & Society of Genitourinary Reconstructive Surgeons (GURS) Symposium
|
|
Learning Objectives:
At the end of this session, attendees should be able to:
- Recall the latest developments in the field of reconstructive urology
- Recognize the current approaches to manage urethral strictures
- Discuss patient cases seen routinely in clinical practice
- Describe techniques recommended for complex reconstruction
- Develop their network and critical thinking by interacting with experts in reconstructive urology from across the globe and participating in clinical discussions
|
|
1000-1130
|
|
Instructional Course: Novel BPH Therapies – Review of Technologies and Practical Instruction (Laser EEP, UroLift, Rezum, Aquablation, Stents)
Chair: Dean Elterman, Canada
|
|
Learning Objectives:
At the end of the session, attendees will be able to:
- Understand the mechanism of action and technique for each of the novel BPH therapies
- Select the best patients for each procedure type based upon patient and prostate characteristics
- Gain knowledge of the clinical data supporting the use of each modality
- Understand best-practice technique for each modality based upon the literature and expert opinion
- Gain an appreciation for the challenges encountered and troubleshooting for each technology
- Appreciate the “tips & tricks” provided by the experts for performing these novel BPH therapies.
Faculty:
- Enrique Rijo, Barcelona
- Vincent Misrai, Toulouse
- Kevin C. Zorn, Canada
- Naeem Bhojani, Canada
- Vineet Gauhar, Singapore
- Bilal Chughtai, United States
|
|
|
|
1000-1130
|
|
Instructional Course: Testosterone Replacement Therapy: An Update on What You Need to Know for Safe Prescribing in Men with Pre-existing Prostate and Cardiovascular Disease and the Impact of COVID-19
Chair: Brian Birch, United Kingdom
|
|
Learning Objectives:
At the end of this session, attendees will be able to:
- Identify and distinguish between the different models of testosterone interaction with the prostate and the implications that these have for clinical practice.
- Apply the basic science evidence that underpins the interaction between testosterone and the cardiovascular system to clinical settings.
- Counsel patients appropriately regarding testosterone replacement therapy and efficacy of treatment.
- Counsel patients appropriately regarding testosterone replacement therapy and cardiovascular disease risk.
- Counsel patients appropriately regarding testosterone replacement therapy and prostate disease risk.
- Counsel patients appropriately regarding testosterone replacement therapy and interactions with COVID-19.
- Contribute to a safer and more appropriate prescribing practice for testosterone replacement therapy.
|
|
1000-1200
|
|
French Urology Around the World Symposium
|
|
1000-1200
|
|
Interactive Session: Medico-Legal Aspects in Urology: Global Challenges
Co-Chairs: Joe Philip, United Kingdom / Rajeev T P, India
|
|
Learning Objectives:
At the end of this session, attendees will:
- Be familiar with the variation in medico legal issues and challenges in different regions of the world
- Understand the definition of clinical negligence and the justification for compensation for the different level of negligence
- Understand the reasons for litigation, the risk factors involved and the reasons for claims
- Be familiar with the importance of proper consent and how to manage the risks
- Understand the importance of proper maintenance of records and audit of outcomes and complications
|
|
1000-1003
|
|
Welcome and Introductions
|
|
1003-1015
|
|
Challenges and solutions in Asia
Lalit Shah, India
|
|
1015-1027
|
|
Challenges and solutions in Europe
Jenni Lane, United Kingdom
|
|
1027-1039
|
|
Challenges and solutions in North America
Ajay Singla, United States
|
|
1039-1051
|
|
Challenges and solutions in Africa
|
|
1051-1103
|
|
Handling complaints: The management perspective
|
|
1103-1115
|
|
Current Trends in Medicolegal aspects in Urology
Jeremy Yuen-Chun Teoh, Hong Kong
|
|
1115-1127
|
|
How do you handle the complaint as an individual?
|
|
1127-1157
|
|
Discussion
|
|
1057-1200
|
|
Concluding remarks
|
|
|
1000-1200
|
|
Joint SIU - Korean Urological Association (KUA) Symposium
Co-Chairs: Christopher Evans, United States / Sung Kyu Hong, South Korea
|
|
1000-1200
|
|
Joint SIU-Confederación Americana de Urología (CAU) Session (in English)
|
|
1000-1200
|
|
SIU Tips and Tricks - Pt 2 SIUJ - Tips & Tricks in Urologic Publishing
Chair: Peter Black, Canada
|
|
Learning Objectives:
At the end of this session, attendees will be able to:
- Recognize the pros and cons of open access publishing and open peer review
- Identify the requisite characteristics of a reputable journal and distinguish such journals from predatory journals
- Understand the components of a high-quality peer review of a journal article
|
|
1000-1005
|
|
Introduction
Peter Black, Canada
|
|
1005-1020
|
|
Urologic Publishing in 2022
|
|
1020-1045
|
|
Controversies in Urologic Publishing - Roundtable Discussion
Moderator: Peter Black, Canada
|
|
1045-1100
|
|
Q&A
|
|
1100-1120
|
|
Recognizing and Avoiding Pseudojournals in Urology
|
|
1120-1130
|
|
Q&A
|
|
1130-1150
|
|
Tips & Tricks for Peer Review
|
|
1150-1155
|
|
Q&A
|
|
1155-1200
|
|
Closing remarks
|
|
|
1000-1200
|
|
Workshop: Laparoscopy for Beginners (EBLUS Curriculum )
Coordinators: Bhavan Rai Prasad, United Kingdom / Rajan Veeratterapillay, United Kingdom
|
|
1300-1430
|
|
Instructional Course: Varicocele and Male Infertility: Uncovering the Facts by an Evidence Based Approach
Chair: Ashok Agarwal, United States
|
|
Learning Objectives
At the end of this session, attendees will increase their knowledge regarding:
- Mechanisms of varicocele-mediated male infertility with focus on the role of seminal oxidative stress (OS), sperm DNA fragmentation (SDF), proteomics, epigenetics and genetics,
- The management of infertile men with varicocele and abnormal semen parameters in light of the most recent studies, systematic reviews, meta-analyses and recommendations of the professional societies.
- Updates on the management of infertile men with varicocele and non-obstructive azoospermia (NOA) based on the most recent research data and guidelines of the professional societies.
- Current clinical practice patterns in the management of varicocele in infertile men guided by the results of a recent global survey conducted by our group.
|
|
1300-1315
|
|
Mechanisms of varicocele-mediated male infertility: Role of oxidative stress, sperm DNA fragmentation, proteomics, epigenetics and genetics
Ashok Agarwal, United States
|
|
1315-1330
|
|
The best treatment option of infertile men with varicocele: Medical, surgical or ART?
Hussein Kandil, United Arab Emirates
|
|
1330-1345
|
|
How to manage infertile men with varicocele associated with non-obstructive azoospermia?
Ramadan Saleh, Egypt
|
|
1345-1400
|
|
Consensus and Diversity in the management of infertile men with varicocele: Results of global practice survey
Rossella Cannarella, United States
|
|
1400-1430
|
|
Moderated Session: Questions & Answers
|
|
|
1300-1430
|
|
Instructional Course: Virtual Care,TeleUrology, Digital Health - Full Complement of Patient-Centred Urologic Care: The Time Is Now!
Chair: Emmanuel Abara, Canada
|
|
Learning Objectives:
At the end of this session, attendees will be able to:
- Understand the path we have travelled with Virtual Care.TeleUrology .Digital Health and the Future.
- Analyze the needs of our patients, the services we can provide and the balance.
- Create Guidelines with appropriate resources available and region sensitive.
- Understand various Regulatory, Legal ,Patient Privacy issues, Re-imbursement patterns -world-wide ,with some examples.
- Enumerate some Challenges and Opportunities in Virtual Care TeleUrology.Digital Health and how we can close gaps and disparities.
|
|
1300-1303
|
|
Welcome and Introduction
Emmanuel Abara, Canada
|
|
1303-1315
|
|
Where did we come from? Where are we? Where are we heading to?
Emmanuel Abara, Canada
Zaki Almallah, United Arab Emirates
|
|
1315-1319
|
|
Q&A
|
|
1319-1331
|
|
What do our patients need or want? What can we offer them? Where is the balance? A role for Guidelines appropriate with resources?
Sunil Shroff, India
|
|
1331-1335
|
|
Q&A
|
|
1335-1347
|
|
What Regulatory Processes, Legal Aspects, Policy Affairs and Re-imbursement 'hurdles' should we be aware of?
Aaron D. Martin, United States
|
|
1347-1351
|
|
Q&A
|
|
1351-1403
|
|
Teleurology Implementation: Practical Points, Different Places and Perspectives?
Zaki Almallah, United Arab Emirates
|
|
1403-1407
|
|
Q&A
|
|
1407-1419
|
|
What are the Challenges and Opportunities for Virtual Care. TeleUrology. Digital Health: Now and Going Forward?
Emmanuel Abara, Canada
|
|
1419-1423
|
|
Q&A
|
|
1423-1430
|
|
Summary / Take Home Message
|
|
|
1300-1500
|
|
Interactive Session: Recurrent UTIs
Chair: Bhaskar K. Somani, United Kingdom
|
|
1300-1500
|
|
Interactive Session: Women in Urology - Leading the Way!
Co-Chairs: Caroline Moore, United Kingdom / Amelia Pietropaolo, United Kingdom / G Laxman Prabhu, India
|
|
Learning Objectives:
At the end of this session, attendees will understand:
Learning Objectives
- How to overcome gender bias- if there is any ?
- How to find a place in all spheres of urological work
- How to ensure gender parity in scientific panels ?
- How to play a bigger role than before and reach leadership positions
- How can urology become more appealing to female medical students
- How can we be an example of gender neutral team work
|
|
1300-1500
|
|
Joint SIU / European Association of Urology (EAU) Symposium
Co-Chairs: Christopher R Chapple, United Kingdom / Christopher Evans, United States
|
|
1300-1315
|
|
Robotic surgery in reconstructive urology: how appropriate is this?
Christopher R Chapple, United Kingdom
|
|
1320-1340
|
|
EAU-SIU Discussion/Audience Participation - Will robotic surgery be standard in reconstructive urology worldwide?
|
|
1340-1355
|
|
“Gold standard” for female stress incontinence: synthetic slings, injectables, colposuspension, autologous slings, the artificial sphincter?
|
|
1355-1410
|
|
Biomarkers in advanced urothelial cancer
|
|
1410-1425
|
|
Precision Medicine in Advanced Prostate Cancer
|
|
1425-1440
|
|
PSMA Ligand therapy
|
|
1440-1500
|
|
Q&A
|
|
|
1300-1500
|
|
Master Videos: Complications in Minimally Invasive Urology and How to Handle?
Co-Chairs: Greg Boustead, South Africa / Ravindra Sabnis, India
|
|
Learning Objectives:
At the end of this session, the attendees should:
- Have a clear overview of scope, severity and management of potential complications in the context of where they practice urology around the globe
- Understand the principles of emergency intra-operative management, organ preservation and salvage.
- Recognition and prevention of intermediate and long term complications
- Principles of minimizing risk of litigation related to iatrogenic injuries
- Pre-operative counselling/Informed consent
- Incorporating the WHO Surgical Checklist into Endourology
- “Calling in the Cavalry” – don't be afraid to ask for help
|
|
1300-1500
|
|
International Neuro-Urology Society (INUS) Symposium
Co-Chair: Blayne Welk, Canada
|
|
Learning Objectives:
At the end of the session, the audience will:
- Understand the physiological mechanisms behind normal and abnormal voiding
- Review the impact of common neurologic diseases on bladder function
- Identify 5 key points for common treatment modalities used in neuro-urology
- Apply key knowledge in the management of example neurourology scenarios
|
|
1300-1310
|
|
Welcome & Introduction of Faculty/INUS & Opening Case
Blayne Welk, Canada
|
|
1310-1320
|
|
Neurophysiology and pathophysiology of voiding
|
|
1320-1350
|
|
Overview of common neurologic diseases and resulting urinary dysfunction: Cerebral: Parkinsons - Spinal: SCI - Pediatric: Spina bifida
|
|
1350-1410
|
|
Treatment in Neuro-urology: Just the essentials
|
|
|
|
Catheters & Anticholinergics/Beta-3s
Blayne Welk, Canada
|
|
|
|
Botulinum toxin & Neuromodulation
|
|
1410-1455
|
|
Panel Case Discussion & Audience Questions
|
|
1455-1500
|
|
Concluding Remarks
|
|
|
1300-1500
|
|
Interactive Session: Global Young Consultants Forum: Shaping your Urology Career
Chair: Belthangady Monu Zeeshan Hameed, India
Co-Chairs: Gabriela Caballero, Mexico / Etienne Xavier Keller, Switzerland
|
|
Learning Objectives:
At the end of this session, attendees will:
- Be able to recognize when themselves or another colleague have burnout known as loss of enthusiasm for work, feelings of cynicism, and a low sense of personal accomplishment. Know how to recognize the symptoms of burned out, and to seek professional advice, build resilience and be able to prevent always type burnout prior to develop symptoms.
- Acquire the knowledge of actual technologies in stents, that the ideal stent has not been designed yet and research is being developed to improve tolerance and newer and better
- Focus on their learning laparoscopy curve and that it may vary among individual surgeons, and understand that there’s a minimum number of cases to achieve proficiency.
- Have the knowledge of actual treatment of PFUD because these injuries vary worldwide, with a great difference reported between developing and developed countries.
|
|
1300-1700
|
|
Symposium on Focal Therapy for Renal and Prostate cancer
Co-Chairs: Jurgen Futterer, The Netherlands / Rafael Tourinho-Barbosa, Brazil
|
|
Learning Objectives:
Coming soon
Each lecture is 13 minutes in length, followed by two minutes of Q&A.
|
|
1300-1305
|
|
Welcome and Introductions
Moderators
Jurgen Futterer, The Netherlands
Rafael Tourinho-Barbosa, Brazil
|
|
1305-1400
|
|
Diagnosis in prostate cancer
|
|
|
|
Role of mpMRI in diagnosing prostate cancer
Jurgen Futterer, The Netherlands
|
|
|
|
MRI/US fusion biopsy: from the diagnosis to the surveillance after focal therapy
|
|
|
|
Can Micro-ultrasound targeted biopsy replace MRI for PCa diagnosis?
Rafael Tourinho-Barbosa, Brazil
|
|
|
|
What is the standard of care for low and intermediate risk prostate cancer?
|
|
|
|
Ablation should be the modern-day standard
|
|
|
|
No role for ablation - radical prostatectomy remains the gold standard
|
|
|
|
Why treat when you can watch - role of active surveillance
|
|
|
|
Why use the knife when we can use the rays - Stereotactic radiotherapy
|
|
|
|
Interactive Panel Discussion
|
|
1515-1610
|
|
Future perspectives in focal therapy for prostate cancer
|
|
|
|
What are the challenges to make focal therapy available for every PCa patient?
|
|
|
|
Imaging after focal therapy. What is the optimal approach?
|
|
|
|
How to identify success and failure after FT?
|
|
|
|
Discussion
|
|
1610-1655
|
|
Focal therapy for renal cancer
|
|
|
|
The current role of biopsy for renal cancer
|
|
|
|
Percutaneous cryotherapy for Small Renal Masses
|
|
|
|
Radiofrequency ablation for Small Renal Masses
|
|
1655-1700
|
|
Conclusion
Moderators
Jurgen Futterer, The Netherlands
Rafael Tourinho-Barbosa, Brazil
Jean de la Rosette, Turkey
|
|
|
1500-1700
|
|
Workshop: Basics on USG in Urology - Session 1
Coordinators: Anshuman Kapoor, India / Helen Scullion, United Kingdom
|
|
Learning Objectives:
At the end of this session, attendees will be able to:
- Operate an USS machine
- Diagnose common Urological ailments
- Conduct a Transrectal USS
- Do a Transrectal Prostate Biopsy under guidance
- Have a basic understanding of Doppler
|
|
1500-1630
|
|
Instructional Course: Overcoming Access and Quality Barriers in Cancer Care using Disruptive Health Technologies
Chair: Shaheen Alanee, United States
|
|
Learning Objectives:
At the end of this session, attendees will:
- Define the barriers in delivering timely specialized care to patients in remote and underserved areas
- Introduce and evaluate emerging artificial intelligence and mobile technologies.
- Demonstrate health-tech role in improving access to quality cancer care
- Increase urologists and allied healthcare providers engagement in developing these technologies and integrating them into medical practice.
|
|
1500-1630
|
|
Instructional Course: Advanced Ureteroscopy
Chair: Michael Grasso, United States
|
|
Learning Objectives:
At the end of this session, attendees will:
- Reinforce ureteroscopic technique and expand on new innovative treatments
- Comprehensive review of ureteroscopic lithotripsy
- Present current state of the art therapies for upper urinary tract urothelial carcinoma
- Present detailed management strategies for upper urinary tract obstruction
- 5. Reinforce preventative measures and treatment strategies for complications associated with RIRS
|
|
1500-1700
|
|
Hot Topics: Modern Endourological Avenues for Urologists
Co-Chairs: Madhu Agrawal, India / Ben Chew, Canada
|
|
Learning Objectives:
At the end of the session, attendees will be able to :
- Describe and understand challenges in ureteral stent technology and complications regarding infection and biofilm.
- Better understand new technologies such as thulium fibre laser compared to holmium:YAG, the use of suction during endoscopic surgery, new Ureteroscopes and how they fit in today’s world
- Better understand and be able to look at the benefits and downsides of miniaturized instruments during percutaneous nephrolithotomy.
|
|
1500-1700
|
|
Luncheon Symposium
|
|
1500-1700
|
|
Master Videos: Recent Innovations in Transurethral Techniques for Resection of Bladder Tumor
Co-Chairs: José Luis Domínguez-Escrig, Spain / Badrinath Konety, United States
|
|
|
|
1500-1700
|
|
SIU Tips and Tricks - Pt 3 SIU uCare
Chair: Laurence Klotz, Canada
|
|
1500-1700
|
|
Hellenic Urological Association (HUA) Symposium
Co-Chairs: Alivizatos Gerasimos, Greece / Ioannis Gkialas, Greece
|
|
Educational needs and expected educational outcomes:
- Participants are expected to learn from attending scientific presentations on bladder cancer explaining latest scientific data as well as addressing difficulties faced when treating bladder cancer patients.
- The session will provide insights for scientists into clinical application of their research, as well as for clinicians into the scientific basis of their technologies and treatments. Junior scientists and clinicians will get a unique insight into each other’s intertwined knowledge basis.
- Participants will learn how medical professionals apply elements of scientific methods to make critical observations on each patient, prepare accurate diagnoses and effectively treat bladder cancer.
- It is expected that attendees of the session will return to their practice with additional knowledge to treat their bladder cancer patients. They are expected to have improved skills while younger doctors and/or trainees are expected to feel more confident about their knowledge and skills after attending a session describing the latest issues in treating bladder cancer.
- Highlight commonalities (strengths) and gaps (opportunities for improvement) in our practice.
Promoting of active learning and learner engagement:
- Dedicated question and answer time during the sessions
- Opportunity for discussion/ audience participation during the session
- Opportunity for attendees to interact with experts in the field of bladder cancer and create an international consultation network which will enable them to have access to knowledge and improve their skills
|
|
|
|
1500-1700
|
|
EurAsian Urooncology Association (EUA) Symposium
|
